Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Esnault, V. L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Esnault, V. L. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 1362-1364
© 2002 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Radiocontrast media-induced nephrotoxicity in patients with renal failure: rationale for a new double-blind, prospective, randomized trial testing calcium channel antagonists

Vincent L. M. Esnault

Service de Néphrologie-Immunologie Clinique, CHU Hôtel Dieu, Nantes, France

Keywords: atrial natriuretic peptide; radiocontrast; renal failure

The first 10% of the full text of this article appears below.

Risk factors for radiocontrast nephropathy

Humans as well as experimental animals with normal renal function do not usually exhibit acute renal failure following radiocontrast media injection. Experimental radiocontrast-induced renal failure requires various preceding stresses, including subtotal nephrectomy, dehydration, congestive heart failure, inhibition of nitric oxide, or prostaglandin synthesis. The major risk factors for radiocontrast nephropathy in humans are: high doses of contrast media, pre-existing renal failure especially in diabetes mellitus patients, dehydration or decreased effective arterial volume (congestive heart failure, cirrhosis, and nephrotic syndrome), as well as other factors favouring pre-renal failure including angiotensin-converting enzyme inhibitors and non-steroidal anti-inflammatory drugs [1]; multiple myeloma may not be an independent risk factor [2].

Prevention of radiocontrast nephropathy: the classical paradigm

The most simple . . . [Full Text of this Article]

Better prevention of radiocontrast nephropathy: from pathogenesis to treatment

Calcium channel antagonists for the prevention of radiocontrast nephropathy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
S. Detrenis, M. Meschi, S. Musini, and G. Savazzi
Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art
Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1542 - 1550.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
C. D. Cox and J. P. Tsikouris
Preventing Contrast Nephropathy: What Is the Best Strategy? A Review of the Literature
J. Clin. Pharmacol., April 1, 2004; 44(4): 327 - 337.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
U. Hoffmann, M. Fischereder, B. Kruger, W. Drobnik, and B. K. Kramer
The Value of N-Acetylcysteine in the Prevention of Radiocontrast Agent-Induced Nephropathy Seems Questionable
J. Am. Soc. Nephrol., February 1, 2004; 15(2): 407 - 410.
[Abstract] [Full Text] [PDF]